Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 02, 2025 08:00 ET | Source: Eupraxia Pharmaceuticals Inc.

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

Eupraxia Pharmaceuticals Reports Initial One Year Clinical Results from RESOLVE Trial in Patients with Eosinophilic Esophagitis (EoE).
August 12, 2025 16:25 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting...
July 22, 2025 17:17 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
July 08, 2025 07:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
June 02, 2025 18:30 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
May 07, 2025 14:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE)
May 06, 2025 18:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out...
May 05, 2025 07:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI

Eupraxia Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI.
April 24, 2025 17:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) will present at the upcoming investor and scientific conferences in April and May.
March 15, 2024 08:26 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million

NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 15, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the...